A once just imagined world where complex treatments like gene and CAR T-cell therapies brought new hope to people suffering from life-threatening and life-altering diseases is suddenly here today. These products have the potential to fundamentally change the way we treat disease, but upfront costs and long-term durability of response present pricing and market access challenges. Gene therapy specifically, is an emerging field filled with great discoveries and the potential of creating major medical breakthroughs, including new approaches that may provide long-term, life-altering benefits to patients through the one-time administration of therapy. The health care system will need to evolve to be able to support the availability of these medical breakthroughs. Manufacturers and PBMs are exploring new and unique payment and delivery models to accommodate these new therapies.
During this session, the panel will explore the thought processes and steps it takes to navigate these unique arrangements and they will reflect on early lessons learned. The panel will talk about the steps taken and issues considered to get where they are today, why it’s important to start the process early, and the importance for both sides to be willing to consider alternative, innovative solutions to help ensure access to innovative therapies.
The discussion will start with a foundation of novel, one-time therapies with key considerations and opportunities, followed by short-term solutions and finally discussing what some of the longer-term solutions may look like.